• 以固定汇率CER 1 计算，2026年初至今的总销售额增长24.6%，以报告汇率计算增长23.0%，核心产品组合 2 销售额增长24.2% ...
Ipsen delivered strong performance in the third quarter of 2026, with total sales growth of 24.6% at constant exchange rates, driven by continued momentum across Oncology, Rare Disease and ...
Ipsen a enregistré une solide performance au troisième trimestre 2026, avec une croissance de son chiffre d’affaires de 24,6 % à taux de change constants, portée par une dynamique soutenue dans ses ...
Croissance du chiffre d’affaires du Groupe de 24,6 % à taux de change constant1 (TCC) au cours des neuf premiers mois de l’année 2026 ou 23,0 % en données publiées, avec une croissance du portefeuille ...
We are living in an era of extraordinary scientific progress. We can target diseases in ways that were unimaginable a generation ago, develop increasingly sophisticated medicines and explore entirely ...
As the Ipsen team departs for #ESMO2026 in Madrid, one area I am particularly interested in is the growing role of real-world data in helping us understand cancer care beyond the clinical trial ...
Navtemadlin is an investigational oral MDM2 inhibitor being developed as an add-on therapy to ruxolitinib for patients with myelofibrosis who have a suboptimal response to ruxolitinib. The Phase III ...
PARIS, FRANCE, 24 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have ...
Over the years, I’ve seen firsthand how crushing fatigue and relentless itching can define daily life for so many people living with rare cholestatic liver diseases. It disrupts sleep, work and family ...
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and ...
Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraine Dysport is the first botulinum toxin in ...
Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results